Scientists Catalog Thousands of Potential Biomarkers for Inflammatory Bowel Disease
Researchers have identified nearly 10,000 biological markers that could help track disease severity and medication response in patients with Crohn’s and colitis.
Key points
- Researchers identified over 9,000 potential biomarkers for IBD severity and treatment response.
- The study utilized multiomics data from the SPARC IBD cohort across the United States.
- Findings aim to address low response rates and side effects in current Crohn's and colitis treatments.
Researchers have compiled a massive catalog of biological markers that may help track the progression and treatment response of inflammatory bowel disease (IBD). The study, conducted by scientists at Enveda Therapeutics, utilized a large multiomics dataset to identify nearly 10,000 potential indicators related to disease severity and medication efficacy.
Mapping Molecular Signatures
Using data from the Study of a Prospective Adult Research Cohort (SPARC IBD), the team analyzed transcriptomics and proteomics to find signatures across different tissues and diagnoses. They identified 9,678 biomarkers linked to disease severity, 299 associated with specific medication use, and 59 that may predict how a patient responds to therapy. These findings cover both Crohn’s disease and ulcerative colitis, offering a more granular look at how these conditions manifest at a molecular level.
While the catalog is extensive, the researchers emphasize that these signatures are currently intended to generate new hypotheses rather than serve as immediate diagnostic tools. The study notes that current IBD treatments often suffer from low response rates and significant side effects, making better tracking tools a priority. However, before these biomarkers can be used to guide patient care, they must undergo further validation through long-term prospective studies.
The data was sourced from the Crohn’s & Colitis Foundation’s IBD Plexus platform, which integrates electronic health records with biological samples like blood and stool from patients across the United States. What to know: This research is in its early stages and does not change current treatment protocols. Patients should always consult their healthcare provider before making changes to their medication or management plan.
Source Nature Health Sciences — nature.com/articles/s41598-026-80167-z ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.